Roivant Sciences is attracting interest from large pharmaceutical companies for its treatment of inflammatory bowel disease, RVT-3101, which could be worth more than $7B, people familiar with the matter told Bloomberg’s Michelle Davis and Dinesh Nair.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Roivant Sciences should be bought on recent weakness, says Citi
- Roivant Sciences price target raised to $18 from $15 at H.C. Wainwright
- UPDATE — Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
- Roivant Sciences expects cash to fund operations into 2H25
- Roivant Sciences announces upcoming milestones